Kindred Biosciences, Inc., a commercial-stage biopharmaceutical company, engages in developing therapies for pets. Its product pipeline focuses on biologics for a range of indications primarily in dogs and cats. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats; and Zimeta, a dipyrone injection for the control of fever in horses. It also develops KIND-016, a monoclonal antibody for the treatment of atopic dermatitis in dogs; KIND-032, a monoclonal antibody targeting interleukin-4 (IL-4) receptor for the treatment of atopic dermatitis in dogs; KIND-025 a canine fusion protein targeting IL-4 and IL-13 for atopic dermatitis in dogs; KIND-030, a monoclonal antibody targeting canine parvovirus for the prophylactic indication in dogs; KIND-509, an antibody for canine inflammatory bowel disease in dogs; KIND-510a, a long-acting feline recombinant erythropoietin being developed for the management of non-regenerative anemia in cats; and KIND-511, an anti-tumor necrosis factor treatment for newborn foals. The company was incorporated in 2012 and is headquartered in Burlingame, California.
IPO Year: 2013
Exchange: NASDAQ
Website: kindredbio.com
15-12B - Kindred Biosciences, Inc. (0001561743) (Filer)
EFFECT - Kindred Biosciences, Inc. (0001561743) (Filer)
S-8 POS - Kindred Biosciences, Inc. (0001561743) (Filer)
S-8 POS - Kindred Biosciences, Inc. (0001561743) (Filer)
S-8 POS - Kindred Biosciences, Inc. (0001561743) (Filer)
S-8 POS - Kindred Biosciences, Inc. (0001561743) (Filer)
S-8 POS - Kindred Biosciences, Inc. (0001561743) (Filer)
POS AM - Kindred Biosciences, Inc. (0001561743) (Filer)
8-K - Kindred Biosciences, Inc. (0001561743) (Filer)
25-NSE - Kindred Biosciences, Inc. (0001561743) (Subject)
TCW Special Purpose Acquisition Corp. (NYSE:TSPQ), a $464 million blank check company sponsored by The TCW Group, Inc. ("TCW"), announced that it has appointed Nanxi Liu to the Company's Board of Directors. Since April 2021, Ms. Liu has served on the TCW Special Purpose Acquisition Corporation's Advisory Board. She is the Co-Founder and Co-CEO of Blaze Technology, a no-code platform that enables teams to build web applications and internal tools. Ms. Liu co-founded and served as CEO of Enplug, a leading digital signage software company used by Fortune 500 companies, until it was acquired in 2021. She previously co-founded Nanoly Bioscience, a venture-backed biotech company that develops po
TCW Special Purpose Acquisition Corp. (NYSE:TSPQ), a $464 million blank check company sponsored by The TCW Group, Inc. ("TCW"), announced that it has appointed Nanxi Liu to its Advisory Board, effective April 26, 2021. Ms. Liu is Co-Founder and CEO of Enplug, a leading digital signage software company used by Fortune 500 companies, and was named one of Forbes 30 Under 30 and Fortune's 10 Most Promising Women Entrepreneurs. She also co-founded Nanoly Bioscience, a venture-backed biotech company that develops polymers that eliminate the need of refrigeration for vaccines and therapeutics. Ms. Liu serves on the Board of Directors of CarParts.com (NASDAQ:PRTS), a leading online provider of aut
TCW Special Purpose Acquisition Corp. (NYSE:TSPQ), a $464 million blank check company sponsored by The TCW Group, Inc. ("TCW"), announced that it has appointed Nanxi Liu to the Company's Board of Directors. Since April 2021, Ms. Liu has served on the TCW Special Purpose Acquisition Corporation's Advisory Board. She is the Co-Founder and Co-CEO of Blaze Technology, a no-code platform that enables teams to build web applications and internal tools. Ms. Liu co-founded and served as CEO of Enplug, a leading digital signage software company used by Fortune 500 companies, until it was acquired in 2021. She previously co-founded Nanoly Bioscience, a venture-backed biotech company that develops po
Bolt-on Acquisition Accelerates Elanco's Expansion in Pet Health Elanco to host conference call for investment community at 8:00 am Eastern Time Elanco will acquire all outstanding stock of Kindred Biosciences at a price of $9.25 per share, or approximately $440 million, a premium of 52% based on the 30-day average. Transaction brings three potential blockbusters in the development phase, complements existing pipeline, and augments monoclonal antibody R&D capabilities. Increasing Investor Day revenue from innovation expectation by $100 million, to $600 million to $700 million by 2025, with significant opportunity beyond the period. Differentiated, disruptive portfolio in ato
SAN FRANCISCO, June 2, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ:KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive results from a pivotal efficacy study of KIND-030 in dogs infected by parvovirus. The primary endpoint was survival and the results showed 100% survival in the treated group versus 43% survival in the placebo group. KIND-030, a monoclonal antibody targeting canine parvovirus (CPV), is partnered with Elanco Animal Health (NYSE:ELAN). In this randomized, blinded, placebo-controlled study, KIND
SAN FRANCISCO, May 25, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ:KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will present at the Stifel 2021 Virtual Jaws & Paws Conference on June 2 and the LD Micro Invitational XI on June 8. Dr. Richard Chin, Chief Executive Officer, will be available for one-on-one meetings. During this time, investors will have the opportunity to discuss recent developments, study results from key therapeutic programs in development, and upcoming milestones. Conference Details: Stifel 2021 Virtual J
SAN FRANCISCO, May 11, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ:KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the first quarter ended March 31, 2021 and provided updates on its programs. For the first quarter 2021, KindredBio reported net revenues of $2.4 million and a net loss of $9.7 million, or $0.24 per share. "We had a strong start to the year, announcing positive results in a new long-acting interleukin-31 antibody program that has the potential to become a best-in-class therapeuti
NEW YORK, NY / ACCESSWIRE / May 11, 2021 / Kindred Biosciences, Inc. (NASDAQ:KIN) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 11, 2021 at 4:30 PM Eastern Time.To listen to the event live or access a replay of the call - visit https://www.investornetwork.com/event/presentation/78813To receive updates for this company you can register by emailing [email protected] or by clicking get investment info from the company's profile.About Investor NetworkInvestor Network (IN) is a financial content community, serving millions of unique investors market information, earnings, commentary and news on what's trending. Dedicated to both the p
SAN FRANCISCO, May 3, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ:KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will release its first quarter 2021 financial results on May 11, 2021, after the market close. The Company will host a conference call at 4:30 p.m. Eastern time/1:30 p.m. Pacific time that day. Access the call by dialing toll-free (855) 433-0927 from the U.S. or (484) 756-4262 internationally, and using conference ID 7573679. The call will also be webcast live here, with a replay available at that link for 30 days. A
SAN FRANCISCO, April 28, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ:KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that the United States Department of Agriculture (USDA) Center for Veterinary Biologics has accepted efficacy data to support the prophylactic indication for KIND-030. The pivotal efficacy data demonstrated that 0% of the KIND-030 treated dogs developed parvovirus infection while 100% of the placebo-control dogs developed the disease, and also showed 100% survival rate in KIND-030. The efficacy study is part of the overall project data package required for full approval, along with safety, manufacturing and additi
TCW Special Purpose Acquisition Corp. (NYSE:TSPQ), a $464 million blank check company sponsored by The TCW Group, Inc. ("TCW"), announced that it has appointed Nanxi Liu to its Advisory Board, effective April 26, 2021. Ms. Liu is Co-Founder and CEO of Enplug, a leading digital signage software company used by Fortune 500 companies, and was named one of Forbes 30 Under 30 and Fortune's 10 Most Promising Women Entrepreneurs. She also co-founded Nanoly Bioscience, a venture-backed biotech company that develops polymers that eliminate the need of refrigeration for vaccines and therapeutics. Ms. Liu serves on the Board of Directors of CarParts.com (NASDAQ:PRTS), a leading online provider of aut
SAN FRANCISCO, April 20, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ:KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today unveiled positive results in a new long-acting interleukin (IL)-31 antibody program (KIND-039) that integrates the company's novel half-life extension technology. Results from the pharmacokinetic study of the molecule demonstrate that the fully caninized, high-affinity antibody has up to a three-fold longer half-life compared to tirnovetmab. This extended half-life is expected to allow for up to three-fold longer interval between dosing.
Lake Street downgraded Kindred Biosciences from Buy to Hold and set a new price target of $9.25 from $12.00 previously
HC Wainwright & Co. downgraded Kindred Biosciences from Buy to Neutral and set a new price target of $9.25 from $9.00 previously
Aegis Capital downgraded Kindred Biosciences from Buy to Hold and set a new price target of $9.25 from $16.00 previously
Aegis Capital reiterated coverage of Kindred Biosciences with a rating of Buy and set a new price target of $16.00 from $14.00 previously
4 - Kindred Biosciences, Inc. (0001561743) (Issuer)
4 - Kindred Biosciences, Inc. (0001561743) (Issuer)
4 - Kindred Biosciences, Inc. (0001561743) (Issuer)
4 - Kindred Biosciences, Inc. (0001561743) (Issuer)
4 - Kindred Biosciences, Inc. (0001561743) (Issuer)
4 - Kindred Biosciences, Inc. (0001561743) (Issuer)
4 - Kindred Biosciences, Inc. (0001561743) (Issuer)
4 - Kindred Biosciences, Inc. (0001561743) (Issuer)
4 - Kindred Biosciences, Inc. (0001561743) (Issuer)
4 - Kindred Biosciences, Inc. (0001561743) (Issuer)
SC 13G/A - Kindred Biosciences, Inc. (0001561743) (Subject)
SC 13D/A - Kindred Biosciences, Inc. (0001561743) (Subject)
SC 13D/A - Kindred Biosciences, Inc. (0001561743) (Subject)
SC 13D - Kindred Biosciences, Inc. (0001561743) (Subject)
SC 13G/A - Kindred Biosciences, Inc. (0001561743) (Subject)
SC 13D/A - Kindred Biosciences, Inc. (0001561743) (Subject)
SC 13D - Kindred Biosciences, Inc. (0001561743) (Subject)
SC 13G - Kindred Biosciences, Inc. (0001561743) (Subject)
SC 13G - Kindred Biosciences, Inc. (0001561743) (Subject)
SC 13G/A - Kindred Biosciences, Inc. (0001561743) (Subject)